Published in Gut on June 01, 2003
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol (2006) 1.16
Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
The role of positron emission tomography in esophageal cancer. Gastrointest Cancer Res (2008) 0.89
18F-FDG PET imaging for identifying the dynamics of intestinal disease caused by SFTSV infection in a mouse model. Oncotarget (2016) 0.79
Diagnostic and prognostic value of preoperative (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography. Intest Res (2017) 0.75
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol (2000) 2.77
Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg (2001) 2.40
A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med (2000) 2.10
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer (2001) 1.96
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol (2000) 1.92
Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology (1998) 1.76
Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer (1996) 1.69
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer (2002) 1.65
Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg (1998) 1.63
Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology (1998) 1.57
Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med (1998) 1.54
Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol (2002) 1.52
18F-FDG PET detection of colonic adenomas. J Nucl Med (2001) 1.49
Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med (1997) 1.47
In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med (1995) 1.46
Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology (2001) 1.45
Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer (2000) 1.43
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.40
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med (2001) 1.36
Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg (1999) 1.34
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum (2000) 1.32
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg (1999) 1.32
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg (1998) 1.30
Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer (2002) 1.28
F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology (1994) 1.27
Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med (2002) 1.26
Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg (2001) 1.25
Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum (2000) 1.25
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology (1995) 1.24
Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut (1995) 1.23
FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med (1998) 1.22
Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg (2000) 1.20
Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med (1999) 1.19
Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg (2001) 1.19
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer (2001) 1.19
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol (1999) 1.19
Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg (1997) 1.18
Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging (2002) 1.17
PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med (1991) 1.15
Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med (2000) 1.11
FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun (2001) 1.10
Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med (1999) 1.08
The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med (2002) 1.08
The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer (1999) 1.06
Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med (2001) 1.04
Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol (2001) 1.02
Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology (1995) 1.02
Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol (2001) 1.01
Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer (1998) 1.01
Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med (1994) 0.99
Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med (1997) 0.99
Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol (1998) 0.97
The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med (2001) 0.96
Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg (2000) 0.95
Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med (2001) 0.92
Positron emission tomography in colorectal cancer. Best Pract Res Clin Gastroenterol (2002) 0.91
Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol (2001) 0.90
FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr (1996) 0.89
FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging (2002) 0.89
Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med (1995) 0.85
Monitoring liver tumor therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr (1990) 0.85
Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging (2002) 0.81
The clinical application of positron emission tomography to colorectal cancer management. Q J Nucl Med (2001) 0.79
Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging (2001) 0.79
Survival of patients staged by FDG-PET before resection of hepatic metastases from colorectal cancer. Ann Surg (2002) 0.76
Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics (1999) 4.07
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology (1993) 3.18
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal (1997) 3.10
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer (1993) 2.26
Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med (1993) 2.19
Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology (1995) 2.11
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study. Eur J Nucl Med (1999) 1.88
Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology (1999) 1.88
Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology (1999) 1.78
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol (1996) 1.70
Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med (1995) 1.67
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.63
In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med (1993) 1.63
Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies. J Nucl Med (2000) 1.51
Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med (1990) 1.48
Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm (2000) 1.46
The need for better methods to determine release criteria for patients administered radioactive material. Health Phys (1998) 1.44
Bone marrow cell trafficking following intravenous administration. Br J Haematol (1999) 1.43
Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med (1995) 1.42
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med (1999) 1.41
Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans. Radiology (1996) 1.41
Radionuclide imaging metabolic activity of brown adipose tissue in a patient with pheochromocytoma. Exp Clin Endocrinol Diabetes (2004) 1.37
Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology (1999) 1.36
Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med (1997) 1.29
Improved radioimaging and tumor localization with monoclonal F(ab')2. J Nucl Med (1983) 1.26
Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med (1997) 1.24
Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med (1998) 1.19
Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol (1998) 1.17
Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med (1996) 1.15
In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med (1995) 1.14
Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma. J Nucl Med (2000) 1.10
Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med (1993) 1.09
Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging (2008) 1.08
Evaluation of FDG PET in patients with cervical cancer. J Nucl Med (1999) 1.08
Sentinel node localization in oral cavity and oropharynx squamous cell cancer. Arch Otolaryngol Head Neck Surg (2001) 1.07
Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol (1996) 1.07
Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology (1996) 1.06
Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun (2001) 1.06
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med (1998) 1.05
Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol (1991) 1.04
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab (2009) 1.04
Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. J Nucl Med (1996) 1.03
CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med (1994) 1.03
Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res (1992) 1.00
Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging (2004) 0.99
Exposure to strong static magnetic field slows the growth of human cancer cells in vitro. Bioelectromagnetics (1996) 0.98
Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res (1992) 0.97
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab (2009) 0.96
Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab (1993) 0.95
New methods for imaging the breast: techniques, findings, and potential. AJR Am J Roentgenol (1995) 0.95
Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positron-sensitive probe: validation in preclinical studies. J Nucl Med (1995) 0.94
Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med (1996) 0.93
Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Ga-citrate, and 125I-HSA. Eur J Nucl Med (1999) 0.93
Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology (1998) 0.92
Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology (1994) 0.91
Radiology of colorectal cancer. Eur J Cancer (2002) 0.91
Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med (1999) 0.91
To AC or not to AC: that is the question. J Nucl Med (1999) 0.89
Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging (2004) 0.89
Utility of lymphoscintigraphy in directing surgical therapy for melanomas of the head, neck, and upper thorax. Surgery (1987) 0.89
PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging (2004) 0.87
Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol (1998) 0.87
Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. J Urol (1990) 0.87
Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Radiology (1999) 0.87
Semi-quantitative ventilation/perfusion scintigraphy and single-photon emission tomography for evaluation of lung volume reduction surgery candidates: description and prediction of clinical outcome. Eur J Nucl Med (1999) 0.86
Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl Med Biol (1997) 0.86
Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. AJR Am J Roentgenol (1995) 0.86
Simultaneous usage of homologous points, lines, and planes for optimal, 3-D, linear registration of multimodality imaging data. IEEE Trans Med Imaging (1995) 0.85
Bone metastases in pheochromocytoma: comparative studies of efficacy of imaging. Radiology (1986) 0.85
Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med (2000) 0.85
Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET. Ann Nucl Med (1997) 0.84
The use of a vasoconstrictor to improve tumour blood flow in intra-arterial chemotherapy: preliminary report. Nucl Med Commun (1985) 0.84
Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat. Cancer Res (1991) 0.84
Monoclonal antibody radioimmunodetection of human-derived colon cancer. Invest Radiol (1983) 0.83
A fiber-optically coupled positron-sensitive surgical probe. J Nucl Med (1994) 0.83
Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J Nucl Med (1998) 0.83
Radioimmunodiagnosis of human-derived squamous cell carcinoma. Hybridoma (1987) 0.83
Use of 2-[F-18]-fluoro-2-deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. Radiology (1994) 0.82
Stereotactic coordinates from ECT sinograms for radionuclide-guided breast biopsy. J Nucl Med (1996) 0.82
Immunoglobulin-complexed aspartate aminotransferase. Clin Chem (1983) 0.82
Synthesis and biological evaluation of radioiodinated phospholipid ether stereoisomers. J Med Chem (1995) 0.82
Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med (1997) 0.81
Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung. Eur J Nucl Med (1996) 0.81
Morphine-augmented hepatobiliary scintigraphy in the severely ill: caution is in order. Radiology (1990) 0.81
Is enteral administration of fluorine-18-fluorodeoxyglucose (F-18 FDG) a palatable alternative to IV injection? Pre-clinical evaluation in normal rodents. Nucl Med Biol (2002) 0.81
Phosphorus-32 therapy of cystic Grade IV astrocytomas: technique and preliminary application. J Nucl Med (1985) 0.81
Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer. Nucl Med Biol (1999) 0.81
Molecular imaging in thyroid cancer. Cancer Imaging (2010) 0.80
Factors affecting the repeatability of gamma camera calibration for quantitative imaging applications using a sealed source. Phys Med Biol (2015) 0.80
Magnetically-enhanced radionuclide therapy (MERiT): in vitro evaluation. Int J Radiat Oncol Biol Phys (1997) 0.80
Magnetically enhanced radionuclide therapy. J Nucl Med (1994) 0.79
Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: theory of application. Med Phys (1995) 0.79
Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology (1997) 0.79
Evaluation of ion-implanted-silicon detectors for use in intraoperative positron-sensitive probes. Med Phys (1996) 0.79
Biological disposition and imaging of a radioiodinated alkylphosphocholine in two rodent models of breast cancer. J Nucl Med (1996) 0.79
Products of cells cultured from gliomas. VI. Immunofluorescent, morphometric, and ultrastructural characterization of two different cell types growing from explants of human gliomas. Am J Pathol (1987) 0.79